<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072317</url>
  </required_header>
  <id_info>
    <org_study_id>guoweijian-2013-raltitrexed</org_study_id>
    <nct_id>NCT02072317</nct_id>
  </id_info>
  <brief_title>Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer</brief_title>
  <official_title>Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare safety and effectiveness of Chemotherapy
      in Paclitaxel plus raltitrexed plug compare with taxol second-line treatment for advanced
      gastric cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      from the first cycle of treatment (day one) to two month after the last cycle
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Since the date of random to disease progression or any cause of death，the average time is 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel plus raltitrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>taxol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>taxol 135 mg/m2, every three weeks for a cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>taxel plus raltitrexed</intervention_name>
    <description>taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle</description>
    <arm_group_label>Paclitaxel plus raltitrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>taxol</intervention_name>
    <description>taxol 135 mg/m2, every three weeks for a cycle</description>
    <arm_group_label>taxol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18~75 years old 2.Pathological diagnosis of gastric cancer or gastroesophageal junction
        adenocarcinoma 3.patient failed after The first line treatment of 5-Fu and platinum
        ,patient relapse half year after using 5 - Fu and platinum as Postoperative adjuvant
        chemotherapy 4.ECOG 0-1 5.At least one measurable objective tumor lesions
        6.ANC≥1.5*109/L；PLT≥80*109/L；HB≥90g/L；TBI≤1.5(UNL); ALT、AST≤1.5ULN； Cr≤ULN；Ccr≥60ml/min
        7.Expected survival period for 3 months or more 8. patients with voluntary participation,
        and sign the informed consent

        Exclusion Criteria:

          1. Recurrence after transfer have received taxol or docetaxel as first-line
             chemotherapy,If the adjuvant chemotherapy with paclitaxel,From the last chemotherapy
             for 6 months or less

          2. With uncontrollable large pleural or peritoneal effusion

          3. In the near future has a history of myocardial infarction (3 months)

          4. Malignant tumour of the past five years with other organizations to source, but the
             full treatment of cervical carcinoma in situ and except skin basal cell carcinoma and
             squamous cell carcinomas;

          5. With brain metastasis

          6. Severe uncontrolled medical disease or acute infection

          7. Pregnancy or breast-feeding women

          8. Has a long history of chronic diarrhea, or now complete intestinal obstruction
             patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>GUO WEI JIAN, doctor</last_name>
    <phone>13816066360</phone>
    <email>guoweijian1@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUO WEI JIAN, doctor</last_name>
      <phone>13816066360</phone>
      <email>guoweijian1@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Weijian Guo</investigator_full_name>
    <investigator_title>attending</investigator_title>
  </responsible_party>
  <keyword>PFS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

